Pfizer Inc. rea-ffirmed earnings guidance for the Full-Year 2024. For the year, the company expects full-year 2024 revenues to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty and Paxlovid (approximately $5 billion and $3 billion, respectively), approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer?s royalty income from Other (Income)/Deductions into the Revenue line.
Market Closed -
Other stock markets
|
Pre-market 07:11:19 pm | |||
30.03 USD | +1.80% |
|
30.06 | +0.10% |
Jul. 17 | Mark Cuban's Cost Plus to import penicillin to address US shortage | RE |
Jul. 17 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.31% | 167B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+2.52% | 125B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Inc. Re-Affirms Earnings Guidance for the Full-Year 2024